Every respiratory virus season reminds us of an important reality in medicine: many infectious diseases begin the same way.
Fever. Fatigue. Muscle aches. Headache.
These nonspecific symptoms are common to influenza, COVID-19, RSV—and to some of the world's most dangerous viral pathogens.
Recent clinical reviews published in the Canadian Medical Association Journal (CMAJ) bring renewed attention to Ebola virus disease and hantavirus infections, highlighting how easily these diseases can resemble routine viral illnesses during their earliest stages. For laboratory professionals, however, the story is less about the symptoms and more about what happens next: accurate diagnosis depends on molecular testing, biosafety, and laboratory readiness.
"When clinical symptoms overlap, laboratory diagnostics become the deciding factor between routine care and a public health emergency."
Why These Updates Matter
The CMAJ articles are not announcing a new scientific breakthrough. Instead, they serve as a timely reminder that emerging infectious diseases remain an ongoing challenge—and that laboratory diagnostics continue to play a central role in identifying them.
This is particularly relevant because both diseases require laboratory confirmation, yet they differ significantly in transmission, treatment options, and public health implications.
For researchers and diagnostic laboratories, understanding these distinctions helps reinforce why robust molecular workflows remain essential.
Two Viruses, One Diagnostic Challenge
Although Ebola virus and hantavirus belong to different viral families and spread through different routes, they share an important characteristic:
Early clinical presentation alone cannot reliably distinguish them from many common infections.
Patients often present with:
- Fever
- Headache
- Muscle pain
- Fatigue
- Gastrointestinal symptoms
Without laboratory testing, these signs provide few clues about the underlying pathogen.
This diagnostic uncertainty is one reason PCR-based molecular testing remains the cornerstone of confirmation for both diseases.
A Closer Look at Hantavirus
Hantavirus infections remain relatively uncommon in North America, but they carry a high risk of severe disease.
The CMAJ review highlights an important detail that is often overlooked:
While most hantaviruses are acquired through exposure to infected rodents, the Andes virus has demonstrated person-to-person transmission, making it unique within the hantavirus family.
That distinction has important implications for infection prevention and public health surveillance.
Another challenge is the lack of targeted therapies.
Currently:
- No broadly approved vaccine exists.
- No specific antiviral treatment is available.
- Clinical management relies primarily on supportive care.
This makes timely laboratory diagnosis even more valuable, allowing clinicians to monitor patients appropriately and implement infection control measures when necessary.
Ebola: Not All Species Are the Same
When people hear "Ebola," they often think of a single disease. In reality, several Ebola virus species infect humans, and they don't all behave the same way.
The CMAJ review notes that the current outbreak in the Democratic Republic of Congo involves Bundibugyo ebolavirus.
Why does that matter?
Because many of the medical advances made over the past decade—including licensed vaccines and monoclonal antibody therapies—were developed against Zaire ebolavirus, the species responsible for several major outbreaks.
Unfortunately, equivalent approved countermeasures are not yet available for Bundibugyo ebolavirus.
For laboratories, this reinforces the importance of accurate species identification. Confirming the presence of Ebola virus is only part of the diagnostic process; identifying the specific virus involved can influence public health response, treatment considerations, and outbreak management.
Why PCR Remains the Gold Standard
One of the strongest messages from both CMAJ reviews is the continued reliance on polymerase chain reaction (PCR) for definitive diagnosis.
PCR remains indispensable because it offers:
- High analytical sensitivity
- High specificity
- Early detection of viral genetic material
- Reliable differentiation between pathogens with overlapping symptoms
As emerging infectious diseases continue to evolve, molecular diagnostics remain one of the most effective tools for delivering accurate answers when time matters.
Laboratory Readiness Extends Beyond PCR
Successful molecular diagnostics depend on far more than a thermal cycler.
Reliable results begin with:
- Proper sample collection and handling
- High-quality nucleic acid extraction
- Validated reagents
- Precision liquid handling
- Calibrated instrumentation
- Strong quality management practices
Each step contributes to the accuracy and reproducibility of the final result.
For laboratories working in research, clinical diagnostics, or public health, maintaining these standards is essential—not only during outbreaks, but every day.
Looking Ahead
The recent CMAJ reviews may not introduce a new diagnostic technology or groundbreaking discovery, but they reinforce an enduring lesson: dangerous pathogens often look deceptively ordinary at first.
That reality places laboratories at the center of infectious disease response.
As global health threats continue to emerge, investments in molecular diagnostics, quality systems, and laboratory preparedness will remain fundamental to protecting both patients and public health.
Why This Matters for Your Laboratory
Whether your lab supports infectious disease research, develops molecular assays, or performs routine diagnostic testing, dependable workflows are critical to generating results that clinicians and researchers can trust.
At Pro Lab Supply, we support laboratories with high-quality molecular biology reagents, instruments, and consumables designed to help maintain reliable performance across every stage of the molecular workflow.
Explore Our Molecular Biology Solutions
Sources
- Billick MJ, Silverstein WK, Bogoch II. Ebola virus disease. Canadian Medical Association Journal. 2026;198(24):E942.
- Oberweis ML, Blanchard AC, Vaugon E. Hantavirus. Canadian Medical Association Journal. 2026;198(24):E943.
- ScienceDaily. Ebola and hantavirus can start like the flu but turn deadly fast. June 22, 2026.